# EDGAR Filing Document

**Accession Number:** 0001822782
**File Stem:** 0001822782-26-000003
**Filing Date:** 2026-5
**Character Count:** 2884
**Document Hash:** 9ade6a2e04381197fe7dc617ec7d8c26
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001822782-26-000003.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001822782-26-000003

**CONFORMED SUBMISSION TYPE**: C-AR

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Deverra Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001822782

**ORGANIZATION NAME:**
- **EIN:** 843312665
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** C-AR
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 020-33895
- **FILM NUMBER:** 26947249

**BUSINESS ADDRESS:**
- **STREET 1:** 1600 FAIRVIEW AVENUE EAST
- **STREET 2:** SUITE 300
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98102
- **BUSINESS PHONE:** 2144788208

**MAIL ADDRESS:**
- **STREET 1:** 2033 6TH AVE SUITE 600
- **STREET 2:** SUITE 300
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 28121

### Attached PDF Documents

**Attachment 1:** `form_car.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM C

### UNDER THE SECURITIES ACT OF 1933

### Issuer Information

**Name of Issuer:** Deverra Therapeutics, Inc.

**Legal Status:** Corporation

**Jurisdiction of Incorporation/Organization:** DE

**Date of Organization:** 09-11-2020

**Physical Address:** 2033 6th Ave Suite 600, Seattle, WA, 28121

**Issuer Website:** https://www.deverratx.com/

**Is there a Co-Issuer?:** No

### Annual Report Disclosure Requirements

**Current Number of Employees:** 1

**Total Assets (Most Recent Fiscal Year):** $10,077,334.00

**Total Assets (Prior Fiscal Year):** $11,309,047.00

**Cash & Cash Equivalents (Most Recent Fiscal Year):** $1,612.00

**Cash & Cash Equivalents (Prior Fiscal Year):** $114.70

**Accounts Receivable (Most Recent Fiscal Year):** $0.00

**Accounts Receivable (Prior Fiscal Year):** $0.00

**Short-Term Debt (Most Recent Fiscal Year):** $1,435,000.00

**Short-Term Debt (Prior Fiscal Year):** $1,690,073.00

**Long-Term Debt (Most Recent Fiscal Year):** $102,916.80

**Long-Term Debt (Prior Fiscal Year):** $0.00

**Revenues/Sales (Most Recent Fiscal Year):** $696,727.00

**Revenues/Sales (Prior Fiscal Year):** $3,879,188.00

**Cost of Goods Sold (Most Recent Fiscal Year):** $696,727.00

**Cost of Goods Sold (Prior Fiscal Year):** $3,879,188.00

**Taxes Paid (Most Recent Fiscal Year):** $29,694.00

**Taxes Paid (Prior Fiscal Year):** $72,893.00

**Net Income (Most Recent Fiscal Year):** $-1,523,035.00

**Net Income (Prior Fiscal Year):** $-3,718,063.00

### Signatures

**Issuer:** Deverra Therapeutics, Inc.

**Signature:** Michael Yurkowsky

**Title:** CEO and Board Member

---

**Signature:** Michael Yurkowsky

**Title:** CEO and Board Member

**Date:** 05-05-2026

---

**Signature:** NONE

**Title:** NONE

**Date:** 05-05-2026